A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm
Neurological Sciences · 2026-07 · 47 (7)
DOI: 10.1007/s10072-026-09172-4 ↗Kurz gefasst
Scoping Review in der Zeitschrift Neurological Sciences, online erschienen am 15.06.2026. Verfasst von Angelo Torrente und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Clonazepam, Blepharospasm, GABA Modulators. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.
Abstract (Originalsprache)
Background
Benign Essential Blepharospasm (BEB) is a focal dystonia that leads to an increased rate of eyelid closure due to involuntary activation of the orbicularis oculi muscles. In severe cases, daily activities can significantly be affected, with reduced quality of life. Injections of OnabotulinumtoxinA are often used as valid therapeutical option. However, this treatment may not be tolerated by all patients, considering its invasive nature and the need for access to specialized centers. Despite oral agents, such as benzodiazepines (particularly clonazepam), are often used as a first-line treatment, evidence regarding their efficacy remains fragmentary.
Objective
This scoping review aims to evaluate the current evidence for the efficacy of clonazepam for benign essential blepharospasm.
Methods
Articles in English about the use of clonazepam in the treatment of BEB were searched for in three major databases (PubMed, Scopus, Cochrane).
Results
The search yielded 259 results. After screening, 13 papers were sought for retrieval. After assessing their suitability, 2 articles were included in the review: one open-label trial and one case report. Despite some limitations, both showed the effectiveness of clonazepam in BEB.
Conclusion
Although some evidence supports the use of clonazepam in the treatment of BEB, high-quality studies are still needed to clarify aspects such as response rates, optimal dose, and other disease management issues. This information may be useful for clinicians who are unable to refer their patients to specialized centers and must rely on their own experience and anecdotal evidence for patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.
- Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy. roberto.monastero@unipa.it.
Förderung
- Università degli Studi di Palermo
Zitieren
APA
Torrente, A., Alonge, P., Pignolo, A., Lo Mauro, E., Monastero, R., & Labate, A. (2026). A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm. Neurological Sciences, 47(7). https://doi.org/10.1007/s10072-026-09172-4
Vancouver
Torrente A, Alonge P, Pignolo A, Lo Mauro E, Monastero R, Labate A. A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm. Neurological Sciences. 2026;47(7). doi:10.1007/s10072-026-09172-4
BibTeX
@article{Torrente2026,
author = {Torrente, Angelo and Alonge, Paolo and Pignolo, Antonia and Lo Mauro, Eloise and Monastero, Roberto and Labate, Angelo},
title = {A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm},
journal = {Neurological Sciences},
year = {2026},
volume = {47},
number = {7},
doi = {10.1007/s10072-026-09172-4}
}
EUVIMED